Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Was it worth introducing health economic evaluation of innovative drugs in the french regulatory setting : the case of new drugs against Hepatitis C Virus

Abstract : The paper draws lessons from the recent uptake of health economic evaluation of innovative drugs in the French regulatory framework.Taking the example of new direct-acting antivirals against Hepatitis C virus the paper asks whether and how the Cost-Effectiveness (CE) Opinions issued by the French National Health Authority improve the information available to support the pricing decisions.The results show that CE Opinions bring to the fore 3 issues prone to impact the Incremental Cost Utility Ratio and that were not available to the decision-maker through Clinical Opinions or published CUA: the stage of treatment initiation, the modeling of the disease progression and the uncertainty around the efficacy rates.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal.umontpellier.fr/hal-01907811
Contributeur : Accord Elsevier CCSD Connectez-vous pour contacter le contributeur
Soumis le : vendredi 22 octobre 2021 - 10:34:42
Dernière modification le : jeudi 19 mai 2022 - 16:04:06
Archivage à long terme le : : dimanche 23 janvier 2022 - 18:56:07

Fichier

S1098301518361436.pdf
Fichiers produits par l'(les) auteur(s)

Licence


Distributed under a Creative Commons Paternité - Pas d'utilisation commerciale 4.0 International License

Identifiants

Collections

Citation

Valérie Clément, Véronique Raimond. Was it worth introducing health economic evaluation of innovative drugs in the french regulatory setting : the case of new drugs against Hepatitis C Virus. Value in Health, Elsevier, In press, ⟨10.1016/j.jval.2018.08.009⟩. ⟨hal-01907811⟩

Partager

Métriques

Consultations de la notice

73

Téléchargements de fichiers

26